Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Retained Earnings: 2019-2024

Historic Retained Earnings for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$1.6 billion.

  • Beam Therapeutics' Retained Earnings fell 26.67% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 26.67%. This contributed to the annual value of -$1.6 billion for FY2024, which is 31.66% down from last year.
  • Per Beam Therapeutics' latest filing, its Retained Earnings stood at -$1.6 billion for FY2024, which was down 31.66% from -$1.2 billion recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' Retained Earnings registered a high of -$397.6 million during FY2020, and its lowest value of -$1.6 billion during FY2024.
  • For the 3-year period, Beam Therapeutics' Retained Earnings averaged around -$1.3 billion, with its median value being -$1.2 billion (2023).
  • Data for Beam Therapeutics' Retained Earnings shows a maximum YoY tumbled of 95.84% (in 2020) over the last 5 years.
  • Beam Therapeutics' Retained Earnings (Yearly) stood at -$397.6 million in 2020, then tumbled by 93.21% to -$768.3 million in 2021, then tumbled by 37.63% to -$1.1 billion in 2022, then dropped by 12.53% to -$1.2 billion in 2023, then slumped by 31.66% to -$1.6 billion in 2024.